Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

The Mobile Diabetes Mgmt. Study With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Other: Traditional care with paper;   Device: Health-on G App. + Physician Web
Sponsors:   Healthconnect;   Seoul National University Hospital;   Seoul National University Bundang Hospital;   SMG-SNU Boramae Medical Center
Recruiting - verified May 2015

Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Teneligliptin
Sponsor:   National Cerebral and Cardiovascular Center
Not yet recruiting - verified May 2015

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: ASP1941;   Drug: Placebo
Sponsor:   Astellas Pharma Korea, Inc.
Not yet recruiting - verified May 2015

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Not yet recruiting - verified May 2015

A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease

Condition:   Type II Diabetes Mellitus
Intervention:   Dietary Supplement: Musashino T2DM diet
Sponsor:   Celio Technology Inc.
Recruiting - verified May 2015

Prohealth@Home: A Feasibility Study Investigating the Use of a Lifestyle App in People at Risk of Type 2 Diabetes

Condition:   Pre-diabetes
Intervention:   Behavioral: Lifestyle counselling
Sponsor:   University of Plymouth
Recruiting - verified May 2015

A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes

Condition:   Diabetes Mellitus
Interventions:   Drug: BIOD-531;   Drug: Humalog® Mix 75/25
Sponsor:   Biodel
Recruiting - verified May 2015

Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes
Intervention:   Drug: Sitagliptin
Sponsors:   University of Missouri-Columbia;   Muhammad Salam;   Syed Naqvi
Recruiting - verified May 2015

Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Biphasic insulin Aspart 30
Sponsors:   Xijing Hospital;   Xijing Hospital, Fourth Military Medical University;   First Affiliated Hospital of Xi’an Jiaotong University;   Second Affiliated Hospital of Xi'an Jiaotong University;   Shaanxi Provincial People's Hospital;   Chang An Hospital;   Xi’an Gaoxin Hospital;   Xi’an Central Hospital;   Shaanxi Aerospace Hospital
Not yet recruiting - verified April 2015

Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear

Conditions:   Diabetes Mellitus Type 2;   Sensory Neuropathy;   Foot Ulcer, Diabetic
Intervention:   Device: Kyboot shoes
Sponsors:   Sheba Medical Center;   Kybun AG
Not yet recruiting - verified May 2015

Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM

Condition:   Type 2 Diabetes
Interventions:   Drug: Glimepiride;   Drug: Sitagliptin;   Drug: Metformin
Sponsors:   Foundation for the National Institutes of Health;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Juvenile Diabetes Research Foundation;   Amylin Pharmaceuticals, LLC.;   Eli Lilly and Company;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Merck Sharp & Dohme Corp.;   Novartis;   Pfizer;   Takeda
Not yet recruiting - verified May 2015

Nutritional Therapy and Education With Multimedia Application in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Nutritional therapy and education;   Behavioral: Nutritional therapy
Sponsors:   Coordinación de Investigación en Salud, Mexico;   National Council of Science and Technology, Mexico
Active, not recruiting - verified May 2015

EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Device: EndoBarrier SANS
Sponsors:   GI Dynamics;   University Malaya Medical Centre, Lembah Pantai, 59100, Kuala Lumpur, Malaysia
Recruiting - verified May 2015

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: KQ-791;   Drug: Placebo
Sponsor:   Kaneq Bioscience Limited
Not yet recruiting - verified May 2015

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Fox Chase Cancer Center
Not yet recruiting - verified May 2015

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: KD026;   Drug: Placebo;   Drug: Metformin
Sponsor:   Kadmon Corporation, LLC
Recruiting - verified May 2015

Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study

Conditions:   Diabetic Angiopathies;   Bone Diseases, Metabolic
Intervention:   Other: Baseline comparison of microcirculation and bone metabolism
Sponsors:   Tameside General Hospital;   Manchester Metropolitan University
Not yet recruiting - verified April 2015

Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Sevelamer;   Drug: Cholecystokinin;   Drug: Sevelamer placebo;   Drug: Isotonic saline
Sponsors:   University Hospital, Gentofte, Copenhagen;   Sanofi
Recruiting - verified May 2015

Rowing Away From Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Glucose Intolerance;   Hyperglycemia
Intervention:   Other: Indoor rowing
Sponsors:   University of Leicester;   Medtronic;   Wellcome Trust
Enrolling by invitation - verified May 2015

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Condition:   Hyperlipidemia
Intervention:   Drug: Atorvastatin
Sponsor:   Stanford University
Recruiting - verified May 2015

Diabetes Group Prenatal Care

Conditions:   Pregnancy;   Gestational Diabetes;   Type 2 Diabetes
Intervention:   Behavioral: Group prenatal care
Sponsors:   Washington University School of Medicine;   Denver Health Medical Center
Not yet recruiting - verified May 2015

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Recruiting - verified May 2015

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Not yet recruiting - verified April 2015

Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences

Condition:   Diabetes Mellitus
Interventions:   Device: OneTouch Reveal® Mobile APP;   Device: OneTouch Verio® Flex BGMS
Sponsors:   LifeScan;   Bio-Kinetic Europe, Ltd.
Not yet recruiting - verified May 2015

Add Glucokinase Activator to Target A1c

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: TTP399 400 mg;   Drug: TTP399 800 mg;   Drug: Sitagliptin 100 mg;   Drug: Placebo
Sponsor:   TransTech Pharma, LLC.
Recruiting - verified May 2015

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PEX168;   Drug: Simvastatin
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting - verified May 2015

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Bexagliflozin tablets
Sponsor:   Theracos
Recruiting - verified May 2015

Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: HMS5552
Sponsor:   Hua Medicine Limited
Completed - verified May 2015

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

Conditions:   Diabetes Mellitus, Type 2;   Exocrine Pancreatic Insufficiency
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: Omacor® (omega-3-acid ethyl esters)
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Strength Training Regimen for Normal Weight Diabetics

Condition:   Diabetes Mellitus
Intervention:   Behavioral: Exercise Intervention
Sponsors:   Stanford University;   Pennington Biomedical Research Center
Not yet recruiting - verified May 2015

Pharmaceutical Care Program for Type 2 Diabetes Mellitus

Condition:   DIABETES MELLITUS, TYPE 2
Interventions:   Other: PHARMACEUTICAL CARE programe;   Other: Without PHARMACEUTICAL CARE programe
Sponsor:   TABREJ MUJAWAR
Recruiting - verified May 2015

A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Conditions:   Diabetes Mellitus;   Diabetes Mellitus Complications;   Gastroparesis
Interventions:   Drug: RM-131;   Drug: Placebo
Sponsor:   Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2015

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified May 2015

A Sleep and Media Intervention to Improve Adolescents' Metabolic Health and Weight Status

Condition:   Sleep
Interventions:   Behavioral: Sleep and Media Use Intervention;   Behavioral: Study Skills Control Group
Sponsor:   University of Alabama at Birmingham
Recruiting - verified May 2015

Evaluation of Stendo Pulsating Suit on Microcirculation and Endothelial Function in Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Device: Verum Stendo session on V1 and Phantom Stendo session on V2;   Device: Phantom Stendo session on V1 and Verum Stendo session on V2
Sponsor:   Stendo
Recruiting - verified November 2014

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified February 2015

Follow-up Study of Complications of Acute Pancreatitis

Conditions:   Pancreatitis;   Pancreatic Neoplasms;   Metabolic Diseases;   Hypertension, Portal;   Respiratory Failure;   Quality of Life
Intervention:  
Sponsor:   The First Affiliated Hospital of Nanchang University
Recruiting - verified November 2014

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Conditions:   Diabetes;   Obesity
Interventions:   Behavioral: Pre-study dietary and exercise instruction.;   Procedure: Screening examination and oral glucose tolerance test;   Procedure: Euglycemic clamp;   Procedure: VO2max.;   Behavioral: Acute exercise bout;   Procedure: Percutaneous needle muscle biopsies
Sponsors:   Mayo Clinic;   Arizona State University
Recruiting - verified May 2015

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Condition:   Diabetes
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diagnostics Deutschland GmbH
Recruiting - verified May 2015

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: LIXISENATIDE AVE0010;   Drug: metformin
Sponsor:   Sanofi
Recruiting - verified May 2015

Diabetes Effects on Long-Term Implant Survival and Success

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified May 2015

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

Hormonal Mechanisms of Sleep Restriction

Condition:   Insulin Resistance
Interventions:   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: Testosterone;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo
Sponsor:   Los Angeles Biomedical Research Institute
Recruiting - verified May 2015

The Practical Evidence of Antidiabetic Combination Therapy in Korea

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: alogliptin;   Drug: Pioglitazone;   Drug: alogliptin + pioglitazone
Sponsors:   Kun-Ho Yoon;   Takeda
Recruiting - verified May 2015

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Glargine Versus NPH in Patients With Chronic Kidney Disease

Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Disease
Interventions:   Drug: Glargine;   Drug: NPH insulin
Sponsor:   University of Sao Paulo General Hospital
Recruiting - verified September 2014

A Phase 1 Single Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2015

Prospective Metabolic Surgery in T2DM Chinese Subjects

Conditions:   Diabetes;   Obesity
Interventions:   Procedure: Roux-en-Y gastric bypass;   Procedure: Sleeve gastrectomy
Sponsor:   Ethicon Endo-Surgery
Recruiting - verified May 2015

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified May 2015

A Study of Once-Daily RO6811135 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo QD;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Recruiting - verified May 2015

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Effects of Physical Activity in Psychosis

Conditions:   Schizophrenia;   Substance Use
Interventions:   Other: Computer game skills training;   Other: Physical activity
Sponsors:   Sykehuset i Vestfold HF;   Stiftelsen Helse og Rehabilitering;   Norwegian Research network in Severe Mental Illness
Enrolling by invitation - verified May 2015

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

Condition:   Healthy Volunteer, Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: RO6799477
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

Condition:   Diabetes Mellitus Type 2
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diagnostics Deutschland GmbH
Recruiting - verified May 2015

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: BI 187004;   Drug: Placebo;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified May 2015

Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)

Conditions:   Obesity;   Type 2 Diabetes
Intervention:  
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   Sanford-Burnham Medical Research Institute
Recruiting - verified May 2015

A Study to Compare the Effect of Double Doses of Long-acting Insulin Therapies in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified May 2015

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2409021;   Drug: Sitagliptin;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified May 2015

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:  
Sponsors:   British Cardiac Research Trust;   Royal Free Hospital NHS Foundation Trust;   London North West Healthcare NHS Trust;   Barnet and Chase Farm Hospitals NHS Trust;   Diabetes and Obesity Research Network;   Lund University;   Health Diagnostic Laboratory, Inc.
Recruiting - verified May 2015

European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.

Condition:   Type 2 Diabetes, Type 1 Diabetes
Intervention:   Device: Accu-Chek® Insight Insulin Pump
Sponsor:   Hoffmann-La Roche
Completed - verified October 2013

A Smartphone Application to Improve Medication Adherence Among People With Type 2 Diabetes Mellitus in Singapore

Condition:   Diabetes Mellitus
Intervention:   Other: Mobile application
Sponsors:   Singapore General Hospital;   National University, Singapore
Withdrawn - verified May 2015

Metabolic and Hormonal Effects of 5:2 Intermittent Fasting

Conditions:   Obesity;   Diabetes Type 2
Intervention:   Other: Caloric restriction
Sponsor:   Karolinska University Hospital
Recruiting - verified May 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified May 2015

The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes

Condition:   Type 2 Diabetes Mellitus With Hypoglycemia
Intervention:  
Sponsor:   Seoul National University Hospital
Enrolling by invitation - verified May 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified May 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified May 2015

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

Condition:   Diabetic Foot Ulcers
Interventions:   Drug: Gentamicin Topical Gel;   Drug: Ciprofloxacin;   Drug: Doxycycline
Sponsor:   Royer Biomedical, Inc.
Terminated - verified May 2015

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified May 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified May 2015

Hypoglycemia (Low Blood Sugar) and the Heart

Conditions:   Hypoglycemia;   Type 2 Diabetes
Intervention:  
Sponsor:   University of British Columbia
Recruiting - verified May 2015

Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers

Condition:   Healthy Night Shift Workers, Sleep Disorders
Interventions:   Drug: Melatonin 2mg;   Drug: Placebo
Sponsor:   Universitätsklinikum Hamburg-Eppendorf
Recruiting - verified May 2015

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: ISIS-GCCRRx;   Drug: Placebo
Sponsor:   Isis Pharmaceuticals
Completed - verified May 2015

Pharmaceutical Care in Emergency Department

Conditions:   Medication Adherence;   Hypertension;   Diabetes Mellitus
Intervention:   Other: Pharmaceutical care
Sponsors:   Hospital Moinhos de Vento;   Ministry of Health, Brazil
Completed - verified May 2015

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Interventions:   Drug: Regular Insulin;   Drug: Humalog
Sponsor:   Emory University
Recruiting - verified May 2015

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified December 2014

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: sitagliptin;   Drug: placebo;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified May 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

A Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY2605541;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Completed - verified May 2015

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Healthy
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified May 2015

Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DLBS1033;   Drug: placebo tablet of DLBS1033
Sponsor:   Dexa Medica Group
Recruiting - verified May 2015

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2014

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Conditions:   Diabetes Mellitus, Type 2;   Healthy
Interventions:   Drug: Empagliflozin;   Drug: BI 10773
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Non-Alcoholic Fatty Liver Disease in Gestational Diabetes

Condition:   Gestational Diabetes Mellitus in Pregnancy
Interventions:   Other: Subjects with Gestational Diabetes;   Other: Controls without Gestational Diabetes
Sponsor:   University of Florida
Recruiting - verified May 2015

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Condition:   Diabetes
Intervention:   Device: ;Accu-Chek Compact Plus LCM bulk Japan
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2013

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Procedure: Roux-en-Y;   Drug: GIP-infusion;   Drug: GLP-1;   Drug: MMS;   Procedure: Sleeve gastrectomy
Sponsors:   Turku University Hospital;   Lund University;   Sigrid Juselius Foundation;   Academy of Finland
Recruiting - verified May 2015

Patient Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Drug: Technosphere® Insulin (TI) Inhalation Powder
Sponsor:   Mannkind Corporation
Completed - verified May 2015

MARLINA - T2DM : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin 5mg
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

Inflammation and Glycation in a General Adult Population

Condition:   Inflammation
Intervention:  
Sponsors:   Hospital Clinico Universitario de Santiago;   Medtronic
Completed - verified May 2015

Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men

Conditions:   Insulin Resistance;   Type 2 Diabetes
Interventions:   Behavioral: Aerobic Plus Resistance Training Group;   Behavioral: Control Group
Sponsor:   Pennington Biomedical Research Center
Active, not recruiting - verified May 2015

Minocycline and Proteinuria in Diabetic Nephropathy

Condition:   Diabetic Nephropathy
Interventions:   Drug: Minocycline 100 mg po bid for 6 months;   Drug: placebo
Sponsor:   Los Angeles Biomedical Research Institute
Active, not recruiting - verified May 2015

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: BMS-813160;   Drug: Placebo matching with BMS-813160
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified April 2015

Type 2 Diabetes and Exercise Function in Single Leg Exercises

Condition:   Type 2 Diabetes
Intervention:   Other: Single Leg Exercise Training
Sponsor:   University of Colorado, Denver
Recruiting - verified December 2014

Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

Condition:   Normal Non-fluency
Intervention:   Drug: Olanzapine
Sponsors:   Michael Rickels;   University of Pennsylvania
Completed - verified May 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

Investigation of Synbiotic Treatment in NAFLD

Condition:   Non-Alcoholic Fatty Liver Disease
Interventions:   Dietary Supplement: Synbiotic;   Dietary Supplement: Maltodextrin
Sponsors:   University Hospital Southampton NHS Foundation Trust.;   National Institute for Health Research, United Kingdom
Recruiting - verified May 2015

Tertiary Prevention in Type II Diabetes Mellitus in Canary Islands Study

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Intervention to patients;   Behavioral: Intervention to professionals;   Other: Usual care
Sponsors:   Servicio Canario de Salud;   Instituto de Salud Carlos III;   Asociación para la Diabetes de Tenerife ;   Asociación de Diabéticos de Gran Canaria 
Active, not recruiting - verified January 2013

Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Exercise, dietary and educational program
Sponsors:   Hospital Universitario Getafe;   Institute of Diabetes for Older People;   Cardiff University;   Igen Biotech SL;   Chu Hopitaux de Bordeaux;   Hexabio Sarl;   Second University of Naples;   University Hospital, Toulouse;   Universitaet Ulm;   University Ghent;   University of Castilla-La Mancha;   Univerzita Karlova v Praze;   Niche Science & Technology Ltd;   Catholic University of the Sacred Heart;   Vrije Universiteit Brussel
Recruiting - verified May 2015

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide once weekly suspension;   Drug: Exenatide twice daily
Sponsor:   AstraZeneca
Completed - verified May 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified October 2014

Barriers to Physical Activity in People With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Placebo Attention Control;   Other: Supervised Exercise Training
Sponsors:   University of Colorado, Denver;   Colorado Clinical & Translational Sciences Institute
Recruiting - verified December 2014

Korean Post-marketing Surveillance for Onglyza®

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified May 2015

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY2189265;   Drug: Placebo;   Drug: Liraglutide
Sponsor:   Eli Lilly and Company
Completed - verified May 2015

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: ASP1941;   Drug: metformin;   Drug: Placebo
Sponsor:   Astellas Pharma Inc
Completed - verified May 2015

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2015

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

Conditions:   Hypertension;   Diabetes
Interventions:   Drug: Aliskiren vs. hydrochlorothiazide;   Drug: Hydrochlorothiazide
Sponsors:   Sir Mortimer B. Davis - Jewish General Hospital;   Novartis Pharmaceuticals
Withdrawn - verified May 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Safety and Efficacy of Exenatide Injection in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Exenatide, Placebo
Sponsor:   Sun Pharmaceutical Industries Limited
Recruiting - verified September 2012

Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified May 2015

Effect of Dietary Glycemic Index on Beta-cell Function

Conditions:   Impaired Glucose Tolerance;   Oxidative Stress;   Prediabetes;   Impaired Fasting Glucose
Interventions:   Other: low glycemic index diet;   Other: high glycemic index diet plus placebo;   Drug: high glycemic index diet plus N-acetylcysteine
Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System
Recruiting - verified May 2015

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Amylin Pharmaceuticals, LLC.;   Eli Lilly and Company
Active, not recruiting - verified December 2014

Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care

Condition:   Type 2 Diabetes
Interventions:   Procedure: Telemonitoring group;   Procedure: Telemonitoring & Telemedicine;   Other: SMBG
Sponsor:   Chang Hee, Lee
Completed - verified May 2015

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: BI1356 low dose;   Drug: BI1356 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2015

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition:   Atherosclerosis
Interventions:   Drug: Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified May 2015

e-NOBORI Observational Registry of Nobori DES

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Terumo Europe N.V.
Active, not recruiting - verified May 2015

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified May 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Mediators of Atherosclerosis in South Asians Living in America

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Heart Diseases;   Coronary Artery Disease;   Coronary Disease
Intervention:  
Sponsors:   University of California, San Francisco;   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified May 2015

Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified May 2015

Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: acarbose;   Behavioral: lifestyle therapy;   Drug: insulin glargine;   Drug: metformin;   Drug: acarbose;   Behavioral: lifestyle therapy;   Other: Standard glycemic care
Sponsors:   Population Health Research Institute;   Hamilton Health Sciences Corporation
Active, not recruiting - verified May 2015

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Completed - verified April 2015

A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: ASP1941
Sponsor:   Astellas Pharma Inc
Completed - verified May 2015

Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified May 2015

Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified May 2015

Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified May 2015

Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified May 2015

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified May 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified May 2015

Diabetes Support Project: Couples Intervention

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Telephone support and behavior change;   Other: Diabetes self-management education
Sponsors:   State University of New York - Upstate Medical University;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified May 2015

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

Condition:   Nonalcoholic Steatohepatitis
Interventions:   Drug: placebo;   Drug: pioglitazone;   Dietary Supplement: Vitamin E;   Drug: placebo;   Dietary Supplement: Vitamin E;   Drug: Vitamin E placebo
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified May 2015

Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Education + Problem-Solving Training Self-Study;   Behavioral: Education + Group Problem-Solving Training;   Behavioral: Education + Individual Problem-Solving Training;   Behavioral: Usual Care
Sponsors:   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2015

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

Conditions:   Low Birth Weight;   Small for Gestational Age;   Immunodeficiency
Intervention:   Other: Cord blood collection for analysis
Sponsors:   University of Utah;   Department of Health and Human Services
Completed - verified June 2012

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

Metabolic Syndrome in Bone Marrow Transplant Survivors

Condition:   Metabolic Syndrome
Intervention:   Other: Diagnostic exams
Sponsor:   Nationwide Children's Hospital
Terminated - verified May 2015

Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids

Condition:   Non-Alcoholic Fatty Liver Disease
Intervention:   Drug: OMACOR
Sponsors:   University Hospital Southampton NHS Foundation Trust.;   National Institute for Health Research, United Kingdom
Active, not recruiting - verified May 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

Trial of a Cardiac Rehabilitation Program Delivered Remotely Through the Internet

Condition:   Cardiovascular Disease
Intervention:   Behavioral: vCRP
Sponsors:   Simon Fraser University;   Heart and Stroke Foundation of Canada
Completed - verified May 2015

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

Conditions:   Birth Defects;   Type 2 Diabetes;   Preterm Birth
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Study of Duodenal-Jejunal Bypass(DJB) as a Potential Cure for Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Procedure: Duodenal-jejunal Bypass
Sponsors:   Sound Shore Medical Center of Westchester;   Maffucci L, Rangraj M
Completed - verified May 2015

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Conditions:   Diabetes Mellitus, Type 2;   Metabolic Syndrome
Intervention:   Drug: MK0916
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified May 2015

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified May 2015

A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)

Condition:   HDL Cholesterol
Interventions:   Drug: MK0733 / Duration of Treatment: 18 Weeks;   Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified May 2015

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

Conditions:   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention:   Drug: pramlintide acetate
Sponsor:   AstraZeneca
Completed - verified May 2015

Get CardioSmart

You're Invited